Chemoprevention of pancreatic cancer: Characterization of par-4 and its modulation by 3,3′ diindolylmethane (DIM)

Pharmaceutical Research

Volumn 25, Issue 9, 2008, Pages 2117-2124

  Azmi, Asfar Sohail ^a   Ahmad, Aamir ^a   Banerjee, Sanjeev ^a   Rangnekar, Vivek M ^b   Mohammad, Ramzi M ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Apoptosis; B DIM; Chemoprevention; Pancreatic cancer; Par 4

Indexed keywords

3,3' DIINDOLYLMETHANE; CISPLATIN; GEMCITABINE; INDOLE DERIVATIVE; PROSTATE APOPTOSIS RESPONSE 4 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER PREVENTION; CARCINOGENESIS; CELL DEATH; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG FORMULATION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; WESTERN BLOTTING;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DEOXYCYTIDINE; DRUG SYNERGISM; HUMANS; INDOLES; PANCREATIC NEOPLASMS; RECEPTORS, THROMBIN; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 49549124992     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-008-9581-8     Document Type: Article

References (32)

1. D. Li K. Xie R. Wolff J. L. Abbruzzese 2004 Pancreatic cancer Lancet 363 1049 1057
2. F. Bray R. Sankila J. Ferlay D. M. Parkin 2002 Estimates of cancer incidence and mortality in Europe in 1995 Eur. J. Cancer 38 99 166
3. C. J. Wray S. A. Ahmad J. B. Matthews A. M. Lowy 2005 Surgery for pancreatic cancer: recent controversies and current practice Gastroenterology 128 1626 1641
4. H. G. Beger B. Rau F. Gansauge B. Poch K. H. Link 2003 Treatment of pancreatic cancer: challenge of the facts World J. Surg. 27 1075 1084
5. J. D. Berlin M. Rothenberg 2001 Chemotherapy for resectable and advanced pancreatic cancer Oncology (Williston Park) 15 1241 1249
6. S. M. Cowgill P. Muscarella 2003 The genetics of pancreatic cancer Am. J. Surg. 186 279 286
7. E. Rozenblum M. Schutte M. Goggins S. A. Hahn S. Panzer M. Zahurak S. N. Goodman T. A. Sohn R. H. Hruban C. J. Yeo S. E. Kern 1997 Tumor-suppressive pathways in pancreatic carcinoma Cancer Res. 57 1731 1734
8. C. Sun T. Yamato T. Furukawa Y. Ohnishi H. Kijima A. Horii 2001 Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines Oncol. Rep. 8 89 92
9. K. Grunewald J. Lyons A. Frohlich H. Feichtinger R. A. Weger G. Schwab J. W. Janssen C. R. Bartram 1989 High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas Int. J. Cancer 43 1037 1041
10. C. A. Moskaluk R. H. Hruban S. E. Kern 1997 p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma Cancer Res. 57 2140 2143
11. D. Shibata G. Capella M. Perucho 1990 Mutational activation of the c-K-ras gene in human pancreatic carcinoma Baillieres Clin. Gastroenterol. 4 151 169
12. C. Almoguera D. Shibata K. Forrester J. Martin N. Arnheim M. Perucho 1988 Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes Cell 53 549 554
13. C. M. Barton S. L. Staddon C. M. Hughes P. A. Hall C. O'Sullivan G. Kloppel B. Theis R. C. Russell J. Neoptolemos R. C. Williamson 1991 Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer Br. J. Cancer 64 1076 1082
14. C. Caldas S. A. Hahn L. T. da Costa M. S. Redston M. Schutte A. B. Seymour C. L. Weinstein R. H. Hruban C. J. Yeo S. E. Kern 1994 Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma Nat. Genet. 8 27 32
15. E. J. Bernhard W. G. McKenna A. D. Hamilton S. M. Sebti Y. Qian J. M. Wu R. J. Muschel 1998 Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes Cancer Res. 58 1754 1761
16. J. Zhao R. N. Buick 1995 Regulation of transforming growth factor beta receptors in H-ras oncogene-transformed rat intestinal epithelial cells Cancer Res. 55 6181 6188
17. K. Venkatasubbarao M. M. Ahmed M. Mohiuddin C. Swiderski E. Lee W. R. Gower Jr. K. F. Salhab P. McGrath W. Strodel J. W. Freeman 2000 Differential expression of transforming growth factor beta receptors in human pancreatic adenocarcinoma Anticancer Res. 20 43 51
18. M. Barradas A. Monjas M. T. az-Meco M. Serrano J. Moscat 1999 The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression EMBO J. 18 6362 6369
19. S. F. Sells D. P. Wood Jr. S. S. Joshi-Barve S. Muthukumar R. J. Jacob S. A. Crist S. Humphreys V. M. Rangnekar 1994 Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells Cell Growth Differ. 5 457 466
20. V. M. Rangnekar 1998 Apoptosis mediated by a novel leucine zipper protein Par-4 Apoptosis 3 61 66
21. A. Nalca S. G. Qiu N. El-Guendy S. Krishnan V. M. Rangnekar 1999 Oncogenic Ras sensitizes cells to apoptosis by Par-4 J. Biol. Chem. 274 29976 29983
22. M. T. az-Meco M. M. Municio S. Frutos P. Sanchez J. Lozano L. Sanz J. Moscat 1996 The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C Cell 86 777 786
23. M. M. Ahmed D. Sheldon M. A. Fruitwala K. Venkatasubbarao E. Y. Lee S. Gupta C. Wood M. Mohiuddin W. E. Strodel 2008 Downregulation of PAR-4, a pro-apoptotic gene, in pancreatic tumors harboring K-ras mutation Int. J. Cancer 122 63 70
24. Y. Li Z. Wang D. Kong S. Murthy Q. P. Dou S. Sheng G. P. Reddy F. H. Sarkar 2007 Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3′-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells J. Biol. Chem. 282 21542 21550
25. M. Abdelrahim K. Newman K. Vanderlaag I. Samudio S. Safe 2006 3,3′-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5 Carcinogenesis 27 717 728
26. C. J. Bruns M. T. Harbison H. Kuniyasu I. Eue I. J. Fidler 1999 In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice Neoplasia 1 50 62
27. R. J. Reed 1994 Bcl-2 and the regulation of programmed cell death J. Cell Biol. 124 1 6
28. A. Das D. Chendil S. Dey M. Mohiuddin M. Mohiuddin J. Milbrandt V. M. Rangnekar M. M. Ahmed 2001 Ionizing radiation down-regulates p53 protein in primary Egr-1-/-mouse embryonic fibroblast cells causing enhanced resistance to apoptosis J. Biol. Chem. 276 3279 3286
29. K. A. West S. S. Castillo P. A. Dennis 2002 Activation of the PI3K/Akt pathway and chemotherapeutic resistance Drug Resist. Updat. 5 234 248
30. B. N. Fahy M. G. Schlieman S. Virudachalam R. J. Bold 2004 Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer J. Am. Coll. Surg. 198 591 599
31. V. M. Bondar B. Sweeney-Gotsch M. Andreeff G. B. Mills D. J. McConkey 2002 Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo Mol. Cancer Ther. 1 989 997
32. J. R. Testa A. Bellacosa 2001 AKT plays a central role in tumorigenesis Proc Natl Acad Sci USA 98 10983 10985